Vancomicina oral en un paciente pediátrico con colangitis esclerosante primaria y enfermedad inflamatoria intestinal

Pérez Martin, Cristo Yared; Alberto Alonso, José Ramón; González Chávez, Jenifer; Díaz Ruiz, María Pilar; Suárez González, Marta; Merino Alonso, Javier.
Farm. hosp ; 47(6): 297-299, Noviembre - Diciembre 2023. tab
Artículo en Inglés, Español | IBECS (España) | ID: ibc-227544

Documentos relacionados

  1. Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome.
  2. Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation.
  3. Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
  4. [Clinical features of primary sclerosing cholangitis and inflammatory bowel disease].
  5. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
  6. Does early diagnosis and management improve liver-related outcomes in children with inflammatory bowel disease and sclerosing cholangitis?
  7. Letter to editor: effects of vancomycin in primary sclerosing cholangitis with and without inflammatory bowel disease.
  8. Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment.
  9. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
  10. Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.